Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New chemo cocktail shows promise for rare brain tumor patients

NCT ID NCT04755023

Disease control Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two chemotherapy drugs (BCNU and TMZ) given before radiation therapy in 53 people newly diagnosed with a rare type of brain cancer called anaplastic oligodendroglioma. The goal was to see how well the drugs shrank tumors and to learn more about genetic markers that might predict treatment response. The approach aims to improve disease control and guide future treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

53 people

The number who actually took part.

Started

Dec 2005

Finished

Dec 2010

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically proven oligodendroglioma or anaplastic oligoastrocytoma, newly diagnosed, resulting or not from a low grade glioma * Tumor with measurable contrast enhancement (at least 15 mm in diameter) * Surgical procedure limited to a biopsy or partial excision * In the event of partial excision, an early postoperative check-up (\<72 hours) performed at best by MRI, if not by CT, is required. * Time between surgery and inclusion less than or equal to one and a half months (45 days) * Age\> 18 years old; \<70 * Karnofsky index\> 60 * Stable or reduced dose of corticosteroids in the 15 days prior to inclusion * Polynuclear neutrophils\> 1500; platelets\> 100,000 * Bilirubin \<1.25 x UNL; SGOT, SGPT, PAL \<2.5 x UNL * Absence of serious uncontrolled pathology * Patient having received and understood the information and having signed the consent Exclusion Criteria: * Presence of GBM foci within the tumor * Absence of evaluable residue after surgery * Previous chemotherapy or radiotherapy * Unsatisfactory expected monitoring conditions * Pregnant or breastfeeding woman; lack of effective contraception if of childbearing age * History of malignant disease (with the exception of CIS of the cervix and basal cell cancer) * Contraindications related to the examination of the I.R.M.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplastic oligoastrocytoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anaplastic oligoastrocytoma anaplastic oligodendroglioma astrocytoma (excluding glioblastoma) oligodendroglioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oligodendroglioma; oligoastrocytoma

Contacts and locations

Locations

  • Assistance Publique - Hôpitaux de Marseille

    Marseille, 13005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.